Collaborations and Partnerships
Overcoming the impact of chronic inflammation and aging
We are open to establishing collaborations to expand access to our AMTX-100 sequences that support research to make a significant impact in providing lasting relief from chronic, debilitating, and fatal diseases.
We believe scientific innovation begins with universal collaboration and alliance building
Our current collaborators include national and international organizations that manufacture, research, and develop a variety of therapeutic applications.
Amytrx Therapeutics is a team of researchers and business specialists dedicated to scientific innovation in researching and treating inflammatory diseases. This has enabled us to identify a breakthrough in human peptide drugs that can overcome the traditional limitations of many currently used anti-inflammatory therapeutics.
Although innovative therapies for many inflammatory diseases have been on the rise, the majority of these treatments incorporate pharmaceuticals with variable efficacy and some with significant adverse effects. At Amytrx Therapeutics, our mission is to deliver immune-modulating support with our peptide platforms while minimizing harm to the patient in the process.
Beginning with topical solutions in skin disorders, we envision the expansion of AMTX-100 formulations that can effectively address other unmet medical needs wherein inflammation is an underlying cause. With a variety of formulation possibilities such as topical, tablet, injectables, inhalables, eye drops, nasal sprays, and patches, AMTX-100 can be targeted to diseased organs for high concentration localized or systemic delivery. AMTX-100 represents the potential to redefine anti-inflammatory therapeutics for any immune-related disease or condition.
